MYCO.CN

Mydecine Innovations Group Inc.

Financials1059 views5 min read

Mydecine Announces First Quarter 2022 Financial Results and Highlights

Mydecine Innovations Group
DENVER, May 16, 2022 -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today reported financial results and provided a business update for the first quarter of 2022.  “Our team had an ext... Read More...
133 views4 min read

Mydecine To Attend March Investor Conferences

Mydecine Innovations Group
DENVER, March 03, 2022 -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the company will be attending three conferences for investors in March – the 34th Annual Roth Conf... Read More...
118 views5 min read

Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules

Mydecine Innovations Group
DENVER, Feb. 16, 2022 -- Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the inclusion of a novel molecule with potentially heart-safe microdose enabling properties in thei... Read More...
425 views4 min read

Mydecine Welcomes Dr. Victoria Hale as Newest Independent Board Member

Mydecine Innovations Group
VANCOUVER, British Columbia, Feb. 03, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s Board of Directors. Dr. Hale ... Read More...
LOI574 views7 min read

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy to Patients under Health Canada’s Special Access Program

Mydecine Innovations Group
VANCOUVER, British Columbia, Jan. 18, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has signed a Letter of Intent (LOI) with The Newly Instit... Read More...
875 views4 min read

Mydecine Innovations Group Engages JBN Partners, LLC for Marketing Services

Mydecine Innovations Group
VANCOUVER, British Columbia, Jan. 07, 2022 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced that the company has engaged JBN Partners, LLC (“JBN”) to in... Read More...
1066 views8 min read

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Mydecine Innovations Group
DENVER, Dec. 09, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, today announced it has entered into an agreement with an investor to complete a non-brokered priv... Read More...
36 views5 min read

Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson

Mydecine Innovations Group
DENVER, Oct. 05, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it plans to supply its lead drug candidate, MYCO-001, for a multi-site smoking cessation study being con... Read More...
1256 views5 min read

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

Mydecine Innovations Group
DENVER, July 21, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that the Company has filed a new patent fo... Read More...
720 views4 min read

Mydecine to Participate in the ROTH Virtual Healthcare Private Company Forum on June 28th

Mydecine Innovations Group
DENVER, June 23, 2021 -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that Josh Bartch, CEO of Mydecine, will pa... Read More...
458 views6 min read

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

Mydecine Innovations Group
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/DENVER, Jan. 14, 2021 - Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative natu... Read More...
1209 views4 min read

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

Mydecine Innovations Group
DENVER, Jan. 05, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled... Read More...
153 views6 min read

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Mydecine Innovations Group
Leading FDA consultancy firm to advise on drug development and clinical trial pipelineDENVER, Dec. 15, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic m... Read More...
796 views5 min read

Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

Mydecine Innovations Group
Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybinDENVER, Dec. 08, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company com... Read More...
1 views7 min read

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

Mydecine Innovations Group
VANCOUVER, British Columbia, Oct. 19, 2020 -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the ... Read More...
380 views4 min read

Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin

Mydecine Innovations Group
VANCOUVER, British Columbia, Oct. 07, 2020 -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering composition of mat... Read More...
1 views8 min read

Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today

Mydecine Innovations Group
Picture 1Figure 1Figure 1DENVER, Sept. 30, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has officially launched and is available for download today:... Read More...
1105 views11 min read

Mindleap Health Announces The Launch of The World’s First Telehealth Platform For Psychedelic Integration

Mydecine Innovations Group
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/42c4893d-6232-4d13-9d58-b3098cc222bbDENVER, Sept. 24, 2020 --  Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), is pleased to announce that its subsidiary Mindleap Health’s (“Mindleap” ) telehealth platform wil... Read More...
1369 views4 min read

Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets

Mydecine Innovations Group
DENVER, Sept. 15, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine"), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value.Topics that the special committee will discuss include, but limited to, a potential spin out of certain company ... Read More...
371 views6 min read

Mydecine™ Launches World’s First Natural-Sourced cGMP Psilocybin for Global Research, Sales, and Distribution Enterprise

Mydecine Innovations Group
Being Facilitated Under a Schedule 1 Health Canada Dealer’s LicenseDENVER, Aug. 18, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine™") is pleased to announce it is the first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharma... Read More...
941 views16 min read

Mydecine Innovations Group Provides Inaugural Corporate Update in the Expanding Psychedelic Medicines Sector

Mydecine Innovations Group
DENVER, Aug. 12, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" “MIG”), is pleased to provide a corporate update regarding recent advancements and achievements that continues to add shareholder value and position Mydecine as a genuine leader in the ever-expanding fungi and psychedelic sectors. Throug... Read More...
M & A39 views8 min read

Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc. Positioned as a Leader in the Development of Psychedelic Treatments for the Betterment of Veterans

Mydecine Innovations Group
DENVER , July 14, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), is pleased to announce that, further to its press release on June 10, 2020 , it has entered into a definitive share exchange agreement (the "Share Exchange Agreement") for the acquisition (the " Acquisition ") of 100% of NeuroPharm Inc. ("Neu... Read More...
852 views4 min read

Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist

Mydecine Innovations Group
VANCOUVER, British Columbia, June 23, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine") is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee.The new members of the science team will provide scientific expertise and corporate strategy support as Mydeci... Read More...
938 views7 min read

Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation

Mydecine Innovations Group
VANCOUVER, British Columbia , June 12, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (NLBIF) (0NF.F) ("Mydecine"), is pleased to announce the establishment of a research division agreement with Applied Pharmaceutical Innovation ("API"), a translational commercial drug development institute hosted in the University of Alberta's Faculty... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!